Paul Haluska

Paul Haluska

Mayo Clinic Rochester C/o Merck Corporation, 126 E. Lincoln Ave Rahway, New Jersey, 07065 Usa

Direct Impact

Concepts for which Paul Haluska has direct influence:

primary peritoneal
epithelial ovarian
gemcitabine hydrochloride
tumor cells
lapatinib topotecan
phase trial
growth factor

External impact

Concepts related to the work of other authors for which Paul Haluska has influence:

breast cancer subtypes
diabetic ketoacidosis
insulin-like growth
igf-1r expression
hazard ratio
prognostic markers
tissue microarray

Prominent publications by Paul Haluska

KOL-Index: 15 I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal antibody designed to bind and inhibit function of the type I insulin-like growth factor receptor (IGF-1R). Ganitumab was tested in combination ...
Known for
Neoadjuvant Breast | Paclitaxel Pgm | Biomarkers Ganitumab | Hba1c Metformin
KOL-Index: 3 Introduction: Patients with Purkinje cell cytoplasmic autoantibody type 1 (PCA-1-IgG, a.k.a. anti-Yo) classically present with a paraneoplastic syndrome characterized by subacute onset cerebellar ataxia with rapid progression. Recently, a broader spectrum of neurological presentations has been recognized, which include peripheral neuropathy, but detailed case descriptions are lacking. ...
Known for
Autoantibodies Ovarian | Laparotomy Nerve | Pet Exploratory | Neuropathy Pain
KOL-Index: 2 Phase II trial to study the effectiveness of gemcitabine hydrochloride and tanespimycin in treating patients who have recurrent advanced ovarian epithelial or primary peritoneal cavity cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and tanespimycin, work in different ways to stop tumor cells from dividing so they stop growing or die. Detailed Description OBJECTIVES:I. ...
Known for
Subsequent Courses | Aag Determine | Tumor Cells | Months Phase
KOL-Index: 2 RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with topotecan may kill more tumor cells.PURPOSE: This phase II trial is studying how ...

Mayo Clinic Rochester c/o Merck Corporation, 126 E. Lincoln Ave Rahway, New Jersey, 07065 USA

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172